URBN
60
5
DHR
38
-2
ORLY
66
-3
PSX
40
-2
MDT
56
-6
WU
20
-16
NRG
77
8
AVGO
44
4
CAH
53
6
GILD
64
6
LOW
53
4
WAT
64
-4
CRM
65
3
ZION
67
-4
BEN
37
-3
UHS
58
4
RF
63
-6
BSX
66
2
MAR
69
-2
STT
67
-4
URBN
60
5
DHR
38
-2
ORLY
66
-3
PSX
40
-2
MDT
56
-6
WU
20
-16
NRG
77
8
AVGO
44
4
CAH
53
6
GILD
64
6
LOW
53
4
WAT
64
-4
CRM
65
3
ZION
67
-4
BEN
37
-3
UHS
58
4
RF
63
-6
BSX
66
2
MAR
69
-2
STT
67
-4
Financhill
Back

Inovio Pharmaceuticals 10K Form

Sell
23

INO
Inovio Pharmaceuticals

Last Price:
5.53
Seasonality Move:
10.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive INO News And Ratings

See the #1 stock for the next 7 days that we like better than INO

INO Financial Statistics

Sales & Book Value

Annual Sales: $832.01K
Cash Flow: $-28.66M
Price / Cash Flow: 0
Annual Sales: $3.73
Price / Book: 1.48

Profitability

EPS (TTM): -5.11000
Net Income (TTM): $-121.64M
Gross Margin: $0
Return on Equity: -98.72%
Return on Assets: -70.72%

Inovio Pharmaceuticals Earnings Forecast

Key Inovio Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 18 years for INO is 0.00%.
  • The Selling, General & Administrative Expenses for INO have been equal to 5,718.93% of Gross Profit Margin.
  • The Research & Development expenses have been 10,417.73% of Revenue.
  • The Interest Expense is -0.90% of Operating Income.
  • The Net Earning history of INO is -16,239.87% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 13 years.

Inovio Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: INO
CUSIP: 45773H
Website: inovio.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.45
Quick Ratio: 4.25

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

INO Technical Analysis vs Fundamental Analysis

Sell
23
Inovio Pharmaceuticals (INO) is a Sell

Is Inovio Pharmaceuticals a Buy or a Sell?